CO2021015030A2 - Inhibidores del inflamasoma nlrp3 - Google Patents
Inhibidores del inflamasoma nlrp3Info
- Publication number
- CO2021015030A2 CO2021015030A2 CONC2021/0015030A CO2021015030A CO2021015030A2 CO 2021015030 A2 CO2021015030 A2 CO 2021015030A2 CO 2021015030 A CO2021015030 A CO 2021015030A CO 2021015030 A2 CO2021015030 A2 CO 2021015030A2
- Authority
- CO
- Colombia
- Prior art keywords
- nlrp3
- nlrp3 inflammasome
- inflammasome inhibitors
- inhibitors
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se refiere a nuevos compuestos de piridazin-3-il fenol de la Fórmula (I): (I), en donde R1, R2, R3, R4, R5 y Z están definidos en la presente, que inhiben la actividad del inflamasoma de la proteína 3 del receptor tipo NOD (NLRP3). La invención además se refiere a procesos para su preparación, composiciones farmacéuticas y medicamentos que los contienen, y a su uso en el tratamiento de enfermedades y trastornos mediados por NLRP3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962849245P | 2019-05-17 | 2019-05-17 | |
PCT/IB2020/054613 WO2020234715A1 (en) | 2019-05-17 | 2020-05-15 | Nlrp3 inflammasome inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021015030A2 true CO2021015030A2 (es) | 2021-11-30 |
Family
ID=70779818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0015030A CO2021015030A2 (es) | 2019-05-17 | 2021-11-08 | Inhibidores del inflamasoma nlrp3 |
Country Status (22)
Country | Link |
---|---|
US (3) | US11208399B2 (es) |
EP (1) | EP3969441A1 (es) |
JP (1) | JP2022532354A (es) |
KR (1) | KR20220008887A (es) |
CN (1) | CN113784957A (es) |
AR (1) | AR119731A1 (es) |
AU (1) | AU2020277738B2 (es) |
BR (1) | BR112021022796A2 (es) |
CA (1) | CA3138226A1 (es) |
CL (1) | CL2021003012A1 (es) |
CO (1) | CO2021015030A2 (es) |
CR (1) | CR20210552A (es) |
CU (1) | CU20210094A7 (es) |
DO (1) | DOP2021000228A (es) |
EC (1) | ECSP21080740A (es) |
IL (1) | IL287042A (es) |
JO (1) | JOP20210307A1 (es) |
MX (1) | MX2021013941A (es) |
PE (1) | PE20220133A1 (es) |
SG (1) | SG11202111029PA (es) |
TW (1) | TW202110809A (es) |
WO (1) | WO2020234715A1 (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021193897A1 (ja) | 2020-03-27 | 2021-09-30 | アステラス製薬株式会社 | 置換ピリダジン化合物 |
CN116390914A (zh) * | 2020-12-25 | 2023-07-04 | 上海拓界生物医药科技有限公司 | 一类含哒嗪的化合物及其医药用途 |
WO2022166890A1 (zh) * | 2021-02-08 | 2022-08-11 | 南京明德新药研发有限公司 | 取代的哒嗪苯酚类衍生物 |
CN117083272A (zh) | 2021-03-04 | 2023-11-17 | 詹森药业有限公司 | 调节nlrp3的4-烷氧基-6-氧代-哒嗪衍生物 |
MX2023010223A (es) | 2021-03-04 | 2023-09-11 | Janssen Pharmaceutica Nv | Derivados de 4-amino-6-oxo-piridazina que modulan la nlrp3. |
US11319319B1 (en) * | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
BR112023022451A2 (pt) * | 2021-04-28 | 2024-01-02 | Astellas Pharma Inc | Composto triazina substituído |
PE20240126A1 (es) | 2021-05-12 | 2024-01-22 | Hoffmann La Roche | Inhibidores de nlrp3 |
WO2022253936A1 (en) | 2021-06-04 | 2022-12-08 | F. Hoffmann-La Roche Ag | Triazine derivatives and their use in the treatment of cancer. |
CN115433163A (zh) * | 2021-06-05 | 2022-12-06 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
EP4362946A1 (en) * | 2021-06-29 | 2024-05-08 | Zomagen Biosciences Ltd | Nlrp3 modulators |
AR126351A1 (es) | 2021-07-02 | 2023-10-11 | Astrazeneca Ab | Compuestos y sus sales inhibidores del inflamasoma nlrp3 |
IL310264A (en) | 2021-07-21 | 2024-03-01 | Nico Therapeutics Inc | A ring pyridine compound |
WO2023028536A1 (en) | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
WO2023028534A1 (en) | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | Inhibitors of nlrp3 |
WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
CN116102535A (zh) * | 2021-10-22 | 2023-05-12 | 索智生物科技(浙江)有限公司 | 一种含氮化合物、其制备方法及应用 |
KR20230066899A (ko) | 2021-11-08 | 2023-05-16 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
WO2023088856A1 (en) * | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
AR127704A1 (es) | 2021-11-19 | 2024-02-21 | Hoffmann La Roche | Derivados de piridazina inhibidores de nlrp3 |
WO2023129987A1 (en) * | 2021-12-29 | 2023-07-06 | Neumora Therapeutics, Inc. | Pyridazine derivatives as modulators of nlrp3 inflammasome and related methods |
TW202327604A (zh) * | 2022-01-07 | 2023-07-16 | 大陸商藥捷安康(南京)科技股份有限公司 | Nlrp3發炎小體抑制劑及其應用 |
WO2023183943A1 (en) * | 2022-03-25 | 2023-09-28 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
WO2023186020A1 (en) * | 2022-03-31 | 2023-10-05 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Nlrp3 inflammasome inhibitors |
LU501764B1 (en) | 2022-03-31 | 2023-10-02 | Leibniz Inst Fuer Naturstoff Forschung Und Infektionsbiologie E V Hans Knoell Inst Hki | Gasdermin e expression in human t cells as a marker for proinflammatory t cell functions |
WO2023194964A1 (en) * | 2022-04-07 | 2023-10-12 | Takeda Pharmaceutical Company Limited | Fused pyridazine derivatives as nlrp3 inhibitors |
WO2023220715A1 (en) * | 2022-05-13 | 2023-11-16 | Ventus Therapeutics U.S., Inc. | Oxoindolinyl amide derivatives for inhibiting nlrp3 and uses thereof |
US20230365534A1 (en) * | 2022-05-13 | 2023-11-16 | Neumora Therapeutics, Inc. | Modulators of nlrp3 inflammasome and related products and methods |
WO2023232917A1 (en) * | 2022-06-03 | 2023-12-07 | F. Hoffmann-La Roche Ag | Novel compounds |
WO2024006559A1 (en) * | 2022-07-01 | 2024-01-04 | Neumora Therapeutics, Inc. | Modulators of nlrp3 inflammasome and related products and methods |
US20240034735A1 (en) | 2022-07-14 | 2024-02-01 | Ac Immune Sa | Novel compounds |
WO2024012551A1 (zh) * | 2022-07-14 | 2024-01-18 | 南京明德新药研发有限公司 | 氘取代的哒嗪苯并噻吩化合物及其应用 |
WO2024017924A1 (en) * | 2022-07-21 | 2024-01-25 | F. Hoffmann-La Roche Ag | Nlrp3 inhibitors |
US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
TW202406550A (zh) | 2022-08-03 | 2024-02-16 | 瑞士商諾華公司 | Nlrp3炎性小體抑制劑 |
WO2024033845A1 (en) * | 2022-08-10 | 2024-02-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
KR20240022938A (ko) | 2022-08-12 | 2024-02-20 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
CN116789674B (zh) * | 2022-08-24 | 2024-05-24 | 杭州高光制药有限公司 | Nlrp3炎性小体抑制剂 |
WO2024064245A1 (en) | 2022-09-23 | 2024-03-28 | Merck Sharp & Dohme Llc | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 |
WO2024090469A1 (ja) * | 2022-10-26 | 2024-05-02 | アステラス製薬株式会社 | 縮環ピリダジン誘導体 |
WO2024097629A1 (en) * | 2022-10-31 | 2024-05-10 | Ventus Therapeutics U.S., Inc. | Bridged bicyclic heterocycloalkyl pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 inhibitors |
CN117986258A (zh) * | 2022-11-04 | 2024-05-07 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
WO2024094150A1 (en) * | 2022-11-04 | 2024-05-10 | Insilico Medicine Ip Limited | Nlrp3 inflammasome inhibitors and uses thereof |
WO2024099993A1 (en) * | 2022-11-09 | 2024-05-16 | F. Hoffmann-La Roche Ag | Triazinone derivatives as nlrp3 inhibitors |
WO2024099996A1 (en) * | 2022-11-09 | 2024-05-16 | F. Hoffmann-La Roche Ag | Triazinone derivatives as nlrp3 inhibitors |
WO2024099992A1 (en) * | 2022-11-09 | 2024-05-16 | F. Hoffmann-La Roche Ag | Triazinone derivatives as nlrp3 inhibitors |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2510997A1 (fr) | 1981-08-10 | 1983-02-11 | Sanofi Sa | Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant |
PT93060B (pt) | 1989-02-07 | 1995-12-29 | Sanofi Sa | Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem |
FR2663326B2 (fr) | 1989-11-17 | 1992-10-16 | Sanofi Sa | Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant. |
FR2676444B1 (fr) | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
AU2005260102A1 (en) | 2004-05-08 | 2006-01-12 | Novartis International Pharmaceutical Ltd. | 3-aryl-5,6-disubstituted pyridazines |
WO2008058064A1 (en) | 2006-11-07 | 2008-05-15 | Lexicon Pharmaceuticals, Inc. | Amine-linked multicyclic compounds as inhibitors of the proline transporter |
GB0720444D0 (en) * | 2007-10-18 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010128152A1 (en) | 2009-05-07 | 2010-11-11 | Novartis Ag | Fused heterocyclic c-glycosides for the treatment of diabetes |
EP2491050A2 (en) | 2009-10-20 | 2012-08-29 | Novartis AG | Glycoside derivative and uses thereof |
US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
DK2975042T3 (en) | 2010-06-23 | 2019-01-21 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives to inhibit tyrosine kinase activity |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
BR112013003388A2 (pt) | 2010-08-10 | 2016-07-12 | Celgene Avilomics Res Inc | sal de besilato de um inibidor de btk |
US8835472B2 (en) * | 2010-09-02 | 2014-09-16 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
DK2835131T3 (en) | 2010-12-14 | 2017-12-04 | Electrophoretics Ltd | Casein kinase 1 delta inhibitors (CK1 delta) |
CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
CA2833771C (en) | 2011-06-10 | 2021-08-03 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
PT2786996T (pt) | 2011-11-29 | 2016-11-07 | Ono Pharmaceutical Co | Cloridrato de derivado de purinona |
WO2013185082A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Inhibitors of bruton's tyrosine kinase |
MY174339A (en) * | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
PT2892900T (pt) | 2012-09-10 | 2017-11-06 | Principia Biopharma Inc | Compostos de pirazolopirimidina como inibidores de cinase |
SG11201503697TA (en) | 2012-11-28 | 2015-06-29 | Intercept Pharmaceuticals Inc | Treatment of pulmonary disease |
JO3564B1 (ar) | 2013-03-08 | 2020-07-05 | Novartis Ag | ببتيدات وتركيبات لعلاج ضرر المفاصل |
JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
EP2989106B1 (en) | 2013-04-25 | 2016-12-14 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
TR201807321T4 (tr) | 2013-11-05 | 2018-06-21 | Novartis Ag | Farnesoid x reseptörlerinin modüle edilmesi için bileşimler ve yöntemler. |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
AU2014358868A1 (en) | 2013-12-05 | 2016-06-09 | Acerta Pharma B.V. | Therapeutic combination of a PI3K inhibitor and a BTK inhibitor |
US9981926B2 (en) | 2013-12-20 | 2018-05-29 | Novartis Ag | Heteroaryl butanoic acid derivatives |
WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
TN2016000441A1 (en) | 2014-05-13 | 2018-04-04 | Novartis Ag | Compounds and compositions for inducing chondrogenesis. |
CN103965169A (zh) | 2014-05-30 | 2014-08-06 | 彭正中 | 一种化合物及其制备方法与用途 |
WO2016022626A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
MY188048A (en) | 2014-10-24 | 2021-11-12 | Bristol Myers Squibb Co | Indole carboxamide compounds useful as kinase inhibitors |
CN107427468B (zh) | 2014-12-24 | 2022-02-25 | 普林斯匹亚生物制药公司 | Btk抑制剂的部位特异性给药 |
MX2017009408A (es) | 2015-01-20 | 2017-10-02 | Merial Inc | Compuestos antihelminticos, composiciones y metodo para usar los mismos. |
EP3256126B1 (en) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
CN106459049B (zh) | 2015-06-03 | 2020-11-27 | 普林斯匹亚生物制药公司 | 酪氨酸激酶抑制剂 |
US20180282310A1 (en) | 2015-06-10 | 2018-10-04 | Biogen Ma Inc. | Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase |
WO2017059702A1 (en) | 2015-10-09 | 2017-04-13 | Acea Biosciences, Inc | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
KR20180073599A (ko) | 2015-11-04 | 2018-07-02 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 암 치료하는 방법 |
ES2879995T3 (es) * | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US10626116B2 (en) | 2016-01-05 | 2020-04-21 | Jiangsu Hengrui Medicine Co., Ltd. | Crystalline form of BTK kinase inhibitor and preparation method thereof |
US10787433B2 (en) | 2016-01-15 | 2020-09-29 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as EAAT2 activators |
KR101865120B1 (ko) | 2016-06-29 | 2018-06-08 | 숭실대학교 산학협력단 | 테스트 노드 기반의 무선 측위 방법 및 그 장치 |
SG11201811255WA (en) | 2016-06-29 | 2019-01-30 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
EP3272739A1 (en) * | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
EA202090034A1 (ru) | 2017-06-14 | 2020-04-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы модификации сплайсинга рнк |
UY37847A (es) * | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
SG11202002941WA (en) | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
JP2021521200A (ja) | 2018-04-10 | 2021-08-26 | スカイホーク・セラピューティクス・インコーポレーテッド | 癌の処置のための化合物 |
US20210253564A1 (en) | 2018-04-26 | 2021-08-19 | Aurigene Discovery Technologies Limited | Pyridazine Derivatives as SMARCA2/4 Degraders |
-
2020
- 2020-05-05 AR ARP200101272A patent/AR119731A1/es unknown
- 2020-05-15 JO JOP/2021/0307A patent/JOP20210307A1/ar unknown
- 2020-05-15 US US16/874,862 patent/US11208399B2/en active Active
- 2020-05-15 PE PE2021001881A patent/PE20220133A1/es unknown
- 2020-05-15 CN CN202080033109.9A patent/CN113784957A/zh active Pending
- 2020-05-15 US US16/874,905 patent/US11254653B2/en active Active
- 2020-05-15 AU AU2020277738A patent/AU2020277738B2/en active Active
- 2020-05-15 EP EP20727386.3A patent/EP3969441A1/en active Pending
- 2020-05-15 KR KR1020217040928A patent/KR20220008887A/ko unknown
- 2020-05-15 MX MX2021013941A patent/MX2021013941A/es unknown
- 2020-05-15 CA CA3138226A patent/CA3138226A1/en active Pending
- 2020-05-15 CU CU2021000094A patent/CU20210094A7/es unknown
- 2020-05-15 TW TW109116306A patent/TW202110809A/zh unknown
- 2020-05-15 JP JP2021567914A patent/JP2022532354A/ja active Pending
- 2020-05-15 CR CR20210552A patent/CR20210552A/es unknown
- 2020-05-15 BR BR112021022796A patent/BR112021022796A2/pt unknown
- 2020-05-15 SG SG11202111029PA patent/SG11202111029PA/en unknown
- 2020-05-15 WO PCT/IB2020/054613 patent/WO2020234715A1/en unknown
-
2021
- 2021-10-06 IL IL287042A patent/IL287042A/en unknown
- 2021-11-04 DO DO2021000228A patent/DOP2021000228A/es unknown
- 2021-11-08 CO CONC2021/0015030A patent/CO2021015030A2/es unknown
- 2021-11-15 CL CL2021003012A patent/CL2021003012A1/es unknown
- 2021-11-15 EC ECSENADI202180740A patent/ECSP21080740A/es unknown
-
2022
- 2022-01-13 US US17/574,820 patent/US20220251067A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200361899A1 (en) | 2020-11-19 |
IL287042A (en) | 2021-12-01 |
TW202110809A (zh) | 2021-03-16 |
US20220251067A1 (en) | 2022-08-11 |
SG11202111029PA (en) | 2021-12-30 |
AU2020277738A1 (en) | 2021-11-18 |
CA3138226A1 (en) | 2020-11-26 |
CL2021003012A1 (es) | 2022-09-09 |
JP2022532354A (ja) | 2022-07-14 |
CR20210552A (es) | 2021-11-26 |
US11254653B2 (en) | 2022-02-22 |
CU20210094A7 (es) | 2022-06-06 |
KR20220008887A (ko) | 2022-01-21 |
DOP2021000228A (es) | 2021-12-15 |
PE20220133A1 (es) | 2022-01-27 |
JOP20210307A1 (ar) | 2023-01-30 |
ECSP21080740A (es) | 2021-12-30 |
WO2020234715A1 (en) | 2020-11-26 |
AU2020277738B2 (en) | 2023-03-02 |
CN113784957A (zh) | 2021-12-10 |
US20200361898A1 (en) | 2020-11-19 |
AR119731A1 (es) | 2022-01-05 |
MX2021013941A (es) | 2022-03-11 |
US11208399B2 (en) | 2021-12-28 |
EP3969441A1 (en) | 2022-03-23 |
BR112021022796A2 (pt) | 2022-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP21080740A (es) | Inhibidores del inflamasoma nlrp3 | |
CO2021000537A2 (es) | Inhibidores de inflamasoma nlrp3 | |
UY38425A (es) | Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste | |
CO2024001922A2 (es) | Inhibidores de nlrp3 | |
CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
ECSP13013068A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
ECSP13013024A (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
BR112013017316A2 (pt) | compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd) | |
CR11119A (es) | Derivados de indazol oxadiazol sustituidos para uso como agonistas esfingozina 1-fosfato (sip) | |
BR112016028642A2 (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. | |
UY38625A (es) | Compuestos y su uso en el tratamiento del cáncer | |
UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
ECSP21037191A (es) | Pirazoles como moduladores de la hemoglobina | |
CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
AR054048A1 (es) | Compuesto de 2- amino-4-oxo-1,3-tiazol-5- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del mismo para preparar un medicamento | |
CO2022014886A2 (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52 | |
CO2021001174A2 (es) | Inhibidores de ckd8/19 | |
UY38550A (es) | Compuestos inhibidores de inflamasoma nlrp3, composiciones, combinaciones y métodos relacionados | |
CO2024005424A2 (es) | Derivados de amina bicíclicos como moduladores de receptor gabaa α5 | |
CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") |